192 related articles for article (PubMed ID: 36867282)
61. Intrinsic molecular subtypes of breast cancers categorized as HER2-positive using an alternative chromosome 17 probe assay.
Desai NV; Torous V; Parker J; Auman JT; Rosson GB; Cruz C; Perou CM; Schnitt SJ; Tung N
Breast Cancer Res; 2018 Jul; 20(1):75. PubMed ID: 29996866
[TBL] [Abstract][Full Text] [Related]
62. Breast cancer recurrence according to molecular subtype.
Shim HJ; Kim SH; Kang BJ; Choi BG; Kim HS; Cha ES; Song BJ
Asian Pac J Cancer Prev; 2014; 15(14):5539-44. PubMed ID: 25081661
[TBL] [Abstract][Full Text] [Related]
63. Association of GATA3, P53, Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer.
Jacquemier J; Charafe-Jauffret E; Monville F; Esterni B; Extra JM; Houvenaeghel G; Xerri L; Bertucci F; Birnbaum D
Breast Cancer Res; 2009; 11(2):R23. PubMed ID: 19405945
[TBL] [Abstract][Full Text] [Related]
64. A deep learning image-based intrinsic molecular subtype classifier of breast tumors reveals tumor heterogeneity that may affect survival.
Jaber MI; Song B; Taylor C; Vaske CJ; Benz SC; Rabizadeh S; Soon-Shiong P; Szeto CW
Breast Cancer Res; 2020 Jan; 22(1):12. PubMed ID: 31992350
[TBL] [Abstract][Full Text] [Related]
65. Validation of the Xpert Breast Cancer STRAT 4 Assay on the GeneXpert instrument to Assess Hormone Receptor, Ki67, and HER2 Gene Expression Status in Breast Cancer Tissue Samples.
Sewanywa L; Hale M; Michelow P; Mayne E; Wiggill T
Appl Immunohistochem Mol Morphol; 2023 Oct; 31(9):613-620. PubMed ID: 37800656
[TBL] [Abstract][Full Text] [Related]
66. Association of poor prognosis subtypes of breast cancer with estrogen receptor alpha methylation in Iranian women.
Izadi P; Mehrdad N; Foruzandeh F; Reza NM
Asian Pac J Cancer Prev; 2012; 13(8):4113-7. PubMed ID: 23098526
[TBL] [Abstract][Full Text] [Related]
67. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.
Carey LA; Perou CM; Livasy CA; Dressler LG; Cowan D; Conway K; Karaca G; Troester MA; Tse CK; Edmiston S; Deming SL; Geradts J; Cheang MC; Nielsen TO; Moorman PG; Earp HS; Millikan RC
JAMA; 2006 Jun; 295(21):2492-502. PubMed ID: 16757721
[TBL] [Abstract][Full Text] [Related]
68. Surgery time interval and molecular subtype may influence Ki67 change after core needle biopsy in breast cancer patients.
Chen X; Zhu S; Fei X; Garfield DH; Wu J; Huang O; Li Y; Zhu L; He J; Chen W; Jin X; Shen K
BMC Cancer; 2015 Oct; 15():822. PubMed ID: 26514283
[TBL] [Abstract][Full Text] [Related]
69. Clinical evaluation of molecular surrogate subtypes in patients with ipsilateral multifocal primary breast cancer.
Janeva S; Krabbe E; Parris TZ; Nasic S; Sundquist M; Karlsson P; Audisio RA; Olofsson Bagge R; Kovács A
Breast Cancer Res; 2023 Apr; 25(1):36. PubMed ID: 37024949
[TBL] [Abstract][Full Text] [Related]
70. Advancing breast cancer subtyping: optimizing immunohistochemical staining classification with insights from real-world Taiwanese data.
Chang YT; Hong ZJ; Yu JC; Lin WZ; Huang TY; Tsai HH; Feng AC; Hsu KF; Huang CC; Chu CM; Liang CM; Liao GS
Am J Cancer Res; 2023; 13(11):5719-5732. PubMed ID: 38058819
[TBL] [Abstract][Full Text] [Related]
71. Breast cancer-specific survival by clinical subtype after 7 years follow-up of young and elderly women in a nationwide cohort.
Johansson ALV; Trewin CB; Hjerkind KV; Ellingjord-Dale M; Johannesen TB; Ursin G
Int J Cancer; 2019 Mar; 144(6):1251-1261. PubMed ID: 30367449
[TBL] [Abstract][Full Text] [Related]
72. Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer.
Sinn HP; Schneeweiss A; Keller M; Schlombs K; Laible M; Seitz J; Lakis S; Veltrup E; Altevogt P; Eidt S; Wirtz RM; Marmé F
BMC Cancer; 2017 Feb; 17(1):124. PubMed ID: 28193205
[TBL] [Abstract][Full Text] [Related]
73. Concordance of breast cancer biomarker status between routine immunohistochemistry/in situ hybridization and Oncotype DX qRT-PCR with investigation of discordance, a study of 591 cases.
Sechrist H; Glasgow A; Bomeisl P; Gilmore H; Harbhajanka A
Hum Pathol; 2020 Oct; 104():54-65. PubMed ID: 32758491
[TBL] [Abstract][Full Text] [Related]
74. Hormone receptor and HER2 assessment in breast carcinoma metastatic to bone: A comparison between FNA cell blocks and decalcified core needle biopsies.
Zeng J; Piscuoglio S; Aggarwal G; Magda J; Friedlander MA; Murray M; Akram M; Reis-Filho JS; Weigelt B; Edelweiss M
Cancer Cytopathol; 2020 Feb; 128(2):133-145. PubMed ID: 31883437
[TBL] [Abstract][Full Text] [Related]
75. Prognostic implications of the intrinsic molecular subtypes in male breast cancer.
Abdeljaoued S; Lhem B; Nasri M; Adouni O; Goucha GA; Bouzaiene H; Boussen H; Rahal RK; Gamoudi GA
J BUON; 2017; 22(2):377-382. PubMed ID: 28534358
[TBL] [Abstract][Full Text] [Related]
76. BluePrint breast cancer molecular subtyping recognizes single and dual subtype tumors with implications for therapeutic guidance.
Kuilman MM; Ellappalayam A; Barcaru A; Haan JC; Bhaskaran R; Wehkamp D; Menicucci AR; Audeh WM; Mittempergher L; Glas AM
Breast Cancer Res Treat; 2022 Oct; 195(3):263-274. PubMed ID: 35984580
[TBL] [Abstract][Full Text] [Related]
77. Predictive Value of Molecular Subtypes in Premenopausal Women with Hormone Receptor-positive Early Breast Cancer: Results from the ABCSG Trial 5.
Bago-Horvath Z; Rudas M; Singer CF; Greil R; Balic M; Lax SF; Kwasny W; Hulla W; Gnant M; Filipits M
Clin Cancer Res; 2020 Nov; 26(21):5682-5688. PubMed ID: 32546648
[TBL] [Abstract][Full Text] [Related]
78. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry.
Park S; Koo JS; Kim MS; Park HS; Lee JS; Lee JS; Kim SI; Park BW
Breast; 2012 Feb; 21(1):50-7. PubMed ID: 21865043
[TBL] [Abstract][Full Text] [Related]
79. Integrated multi-omics profiling of high-grade estrogen receptor-positive, HER2-negative breast cancer.
Wang K; Li L; Franch-Expósito S; Le X; Tang J; Li Q; Wu Q; Bassaganyas L; Camps J; Zhang X; Li H; Foukakis T; Xiang T; Wu J; Ren G
Mol Oncol; 2022 Jun; 16(12):2413-2431. PubMed ID: 34146382
[TBL] [Abstract][Full Text] [Related]
80. Concordance of RT-qPCR with immunohistochemistry and its beneficial role in breast cancer subtyping.
Li Y; Chen T; Du F; Wang H; Ma L
Medicine (Baltimore); 2023 Sep; 102(38):e35272. PubMed ID: 37746948
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
